Nexturastat A

本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断

一种有效的选择性 HDAC6 抑制剂，IC50 为 5 nM。

A potent and selective HDAC6 inhibitor with IC50 of 5 nM; displays >100-fold selectivity over other HDAC isozymes (600-fold relative to the inhibition of HDAC1).

Western Blot Analysis Cell Line:B16 murine melanoma cells Concentration:0-10 μM Incubation Time:24 h Result:Increased the level of acetyl α-tubulin levels in a dose-dependent.Cell Viability Assay Cell Line:RPMI-8226 and U266 cells Concentration:0-40 μM Incubation Time:48 h Result:Impaired multiple myeloma (MM) cells viability in a dose- and time-dependent manner.Apoptosis Analysis Cell Line:RPMI-8226 and U266 cells Concentration:0, 30, 40 μM Incubation Time:48 h Result:Induced cell apoptosis in human MM cells.RT-PCRCell Line:RPMI-8226 and U266 cells Concentration:30 μM Incubation Time:48 h Result:Increased the levels of p21 mRNA in RPMI-8226 and U266 cells.

——

Nexturastat A

Cell Cycle/DNA Damage

HDAC

HDAC6

Cancer

——

1403783-31-2

341.4042

C19H23N3O3

>98% (HPLC)

DMSO: ≥ 56 mg/mL

O=C(NO)C1=CC=C(CN(CCCC)C(NC2=CC=CC=C2)=O)C=C1

Benzamide, 4-[[butyl[(phenylamino)carbonyl]amino]methyl]-N-hydroxy-

(-20℃)

With Ice Pack

≥ 2 years